C Messiou

Summary

Affiliation: Royal Marsden Hospital
Country: UK

Publications

  1. doi request reprint Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC - STBSG) and Imaging Group recommendations for radiological examina
    C Messiou
    Department of Radiology, The Royal Marsden Hospital, London, UK Electronic address
    Eur J Cancer 56:37-44. 2016
  2. pmc Assessing response of myeloma bone disease with diffusion-weighted MRI
    C Messiou
    Department of Radiology, The Royal Marsden NHS Foundation Trust, Sutton, UK
    Br J Radiol 85:e1198-203. 2012
  3. doi request reprint Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values
    C Messiou
    The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Skeletal Radiol 43:205-8. 2014
  4. doi request reprint Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility
    C Messiou
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT, UK
    Eur Radiol 21:1713-8. 2011
  5. doi request reprint Assessing response in bone metastases in prostate cancer with diffusion weighted MRI
    C Messiou
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, UK
    Eur Radiol 21:2169-77. 2011
  6. pmc Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden
    S L Giles
    MRI Department, Royal Marsden Hospital, Sutton, Surrey, UK Electronic address
    Clin Radiol 70:614-21. 2015
  7. doi request reprint Quantifying sclerotic bone metastases with 2D ultra short TE MRI: a feasibility study
    C Messiou
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, UK
    Cancer Biomark 7:211-8. 2010
  8. pmc Evaluation of lactate detection using selective multiple quantum coherence in phantoms and brain tumours
    L M Harris
    Cancer Research UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    NMR Biomed 28:338-43. 2015
  9. doi request reprint Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring
    C Messiou
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Cancer Biomark 6:21-32. 2010

Collaborators

Detail Information

Publications9

  1. doi request reprint Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC - STBSG) and Imaging Group recommendations for radiological examina
    C Messiou
    Department of Radiology, The Royal Marsden Hospital, London, UK Electronic address
    Eur J Cancer 56:37-44. 2016
    ....
  2. pmc Assessing response of myeloma bone disease with diffusion-weighted MRI
    C Messiou
    Department of Radiology, The Royal Marsden NHS Foundation Trust, Sutton, UK
    Br J Radiol 85:e1198-203. 2012
    ..The relationship between changes in marrow fat and ADC was also explored...
  3. doi request reprint Use of apparent diffusion coefficient as a response biomarker in bone: effect of developing sclerosis on quantified values
    C Messiou
    The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Skeletal Radiol 43:205-8. 2014
    ..To investigate the effect of sclerosis on apparent diffusion coefficient measurements in bone metastases from prostate cancer undergoing treatment...
  4. doi request reprint Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility
    C Messiou
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, SM2 5PT, UK
    Eur Radiol 21:1713-8. 2011
    ..To establish normal bone marrow values of apparent diffusion coefficient (ADC) over an age range, compare them with metastatic and myelomatous involvement, to establish reproducibility and to optimise b values...
  5. doi request reprint Assessing response in bone metastases in prostate cancer with diffusion weighted MRI
    C Messiou
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, UK
    Eur Radiol 21:2169-77. 2011
    ..To determine whether changes in ADC of bone metastases secondary to prostate carcinoma are significantly different in responders compared with progressors on chemotherapy...
  6. pmc Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden
    S L Giles
    MRI Department, Royal Marsden Hospital, Sutton, Surrey, UK Electronic address
    Clin Radiol 70:614-21. 2015
    ....
  7. doi request reprint Quantifying sclerotic bone metastases with 2D ultra short TE MRI: a feasibility study
    C Messiou
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Surrey, UK
    Cancer Biomark 7:211-8. 2010
    ....
  8. pmc Evaluation of lactate detection using selective multiple quantum coherence in phantoms and brain tumours
    L M Harris
    Cancer Research UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    NMR Biomed 28:338-43. 2015
    ..9 ± 1.5 mM, p=0.048). Lactate was not seen in secondary metastases in the brain. SelMQC-CSI is shown to be a useful technique for measuring lactate in tumours whose signals are otherwise contaminated by lipid...
  9. doi request reprint Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring
    C Messiou
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Cancer Biomark 6:21-32. 2010
    ..This article discusses these challenges and reviews the potential of DW-MRI to provide a biomarker of response in metastatic bone disease...